You are here

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics

Respiratory Medicine, pages S2 - S8

Summary

Chronic airway infection and inflammation are key events in the clinical course of cystic fibrosis (CF). The most relevant, best investigated strain of bacteria in these circumstances is Pseudomonas aeruginosa. Since pulmonary infection with P. aeruginosa is localized in the lower conducting airways, treatment is accessible with the use of inhaled aerosolized antibiotics. Tobramycin inhalation solution was the first antibiotic to be developed and approved (in 1998) for use as an aerosolized antibiotic in patients with CF. The only other aerosolized antibiotic indicated for this use is aztreonam lysine solution for inhalation, which has been approved by both European and US authorities. In prospective, randomized, controlled trails, both agents exhibited a very acceptable safety profile, along with an increase in forced expiratory volume in 1 second and other clinically relevant endpoints. New developments focus on such components as reducing the treatment burden by using dry power inhalers, decreasing inhalation frequency to once daily, penetrating P. aeruginosa biofilms, and combining two antibiotics in one solution for inhalation. However, the ideal aerosolized antibiotic regimen for the treatment of chronic P. aeruginosa infection has yet not been selected.

Keywords: Cystic fibrosis, Pseudomonas aeruginosa, Aerosolized antibiotics, FEV1, Tobramycin inhalation solution (TIS), Aminoglycosides, Fluoroquinolones, Aztreonam lysine for inhalation solution (AZLI), Minimum inhibitory concentration (MIC), Polymyxins.

References

  • 1 RL Gibson, JL Burns, BW Ramsey. Pathophysiology and management of respiratory infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918-951 Crossref
  • 2 Cystic Fibrosis Foundation. US Cystic Fibrosis Foundation Annual Registry Report 2009 (Cystic Fibrosis Foundation, Bethesda, MD, 2010)
  • 3 TW Lee, KG Brownlee, SP Conway, M Denton, JM Littlewood. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2:29-34 Crossref
  • 4 M Rosenfeld, BW Ramsey, RL Gibson. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med. 2003;9:492-497 Crossref
  • 5 A Mehrotra. Bacterial biofilms. Pediatr Asthma Allergy Immunol. 2007;20:191-195 Crossref
  • 6 J Emerson, M Rosenfeld, S McNamara, B Ramsey, RL Gibson. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91-100 Crossref
  • 7 A Pamukcu, A Bush, R Buchdahl. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol. 1995;19:10-15 Crossref
  • 8 GM Nixon, DS Armstrong, R Carzino, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138:699-704 Crossref
  • 9 RL Henry, CM Mellis, L Petrovic. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12:158-161 Crossref
  • 10 M Ballmann, P Rabsch, H von der Hardt. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax. 1998;53:732-737 Crossref
  • 11 MR Kosorok, L Zeng, SE West, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32:277-287
  • 12 JC Davies. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care. 2009;54:628-638
  • 13 EC Dasenbrook, CA Merlo, M Diener-West, N Lechtzin, MP Boyle. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:814-821 Crossref
  • 14 EC Dasenbrook, W Checkley, CA Merlo, MW Konstan, N Lechtzin, MP Boyle. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303:2386-2392 Crossref
  • 15 T Bjarnsholt, PO Jensen, MJ Fiandaca, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009;44:547-558 Crossref
  • 16 F Ratjen, A Munck, P Kho, G Angyalosi. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65:286-291 Crossref
  • 17 TA Douglas, S Brennan, S Gard, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2009;33:305-311
  • 18 SM Moskowitz, SJ Silva, N Mayer-Hamblett, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol. 2008;43:874-881 Crossref
  • 19 G Ryan, M Singh, K Dwan. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2011;:CD001021
  • 20 PEA di Sant' Agnese, DH Andersen. Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child. 1946;72:17-61 Crossref
  • 21 SP Conway. Nebulized antibiotic therapy: the evidence. Chronic Respir Dis. 2005;2:35-41 Crossref
  • 22 PM Mendelman, AL Smith, J Levy, A Weber, B Ramsey, RL Davis. Aminoglycoside penetration, inactivation, and efficiency in cystic fibrosis sputum. Am Rev Respir Dis. 1985;132:761-765
  • 23 A Weber, A Smith, J Williams-Warren, B Ramsey, A Smith. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol. 1994;17:331-339
  • 24 AL Smith, BW Ramsey, DL Hedges, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989;7:265-271 Crossref
  • 25 BW Ramsey, HL Dorkin, JD Eisenberg, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328:1740-1746 Crossref
  • 26 A Weber, G Morlin, M Cohen, J Williams-Warren, B Ramsey, A Smith. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol. 1997;23:249-260 Crossref
  • 27 DE Geller, WH Pitlick, PA Nardella, WG Tracewell, BW Ramsey. Pharmacokinetics and bioavailability of aerosolized tobramycin (TOBI®) in cystic fibrosis. Chest. 2002;122:219-226 Crossref
  • 28 J Eisenberg, M Pepe, J Williams-Warren, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest. 1997;111:955-962 Crossref
  • 29 TOBI® (tobramycin inhalation solution) Prescribing Information (Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2009) Available at: www.pharma.us.novartis.com/product/pi/pdf/tobi.pdf (accessed October 3, 2011).
  • 30 BW Ramsey, MS Pepe, JM Quan, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23-30 Crossref
  • 31 RB Moss. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121:55-63 Crossref
  • 32 RB Moss. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120(3 Suppl):107S-113S Crossref
  • 33 TD Murphy, RD Anbar, LA Lester, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38:314-320 Crossref
  • 34 DE Geller, S Madge. Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. Respir Med. 2011;105(Suppl 2):S24-S31 Crossref
  • 35 A Chuchalin, E Csiszér, K Gyurkovics, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs. 2007;9(Suppl 1):21-31 Crossref
  • 36 PA Flume, BP O'Sullivan, KA Robinson, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-969 Crossref
  • 37 Cayston® (aztreonam for inhalation solution). Prescribing Information (Gilead Sciences, Inc., Foster City, CA, 2010) Available at: https://www.cayston.com/assets/media/pdfs/CAYSTON_full_prescribing_information.pdf (accessed October 29, 2011).
  • 38 European Medicines Agency. Cayston. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000996/human_med_000686.jsp&mid=WC0b01ac058001d124 (accessed October 29, 2011).
  • 39 RL Gibson, GZ Retch-Bogart, C Oermann, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006;41:656-665 Crossref
  • 40 GZ Retsch-Bogart, JL Burns, KL Otto, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol. 2008;43:47-58 Crossref
  • 41 GZ Retsch-Bogart, AL Quittner, RL Gibson, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135:1223-1232 Crossref
  • 42 K McCoy, AL Quittner, CM Oermann, RL Gibson, GZ Retsch-Bogart, AB Montgomery. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921-928 Crossref
  • 43 CM Oermann, GZ Retsch-Bogart, AL Quittner, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45:1121-1134 Crossref
  • 44 CM Oermann, KS McCoy, GZ Retsch-Bogart, RL Gibson, M McKevitt, AB Montgomery. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother. 2011;66:2398-2404 Crossref
  • 45 CE Wainwright, AL Quittner, DE Geller, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros. 2011;10:234-242 Crossref
  • 46 CR Hansen, T Pressler, N Høiby. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008;7:523-530 Crossref
  • 47 T Jensen, SS Pedersen, S Garne, C Heilmann, N Høiby, C Koch. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19:831-838
  • 48 ME Hodson, CG Gallagher, JR Govan. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20:658-664 Crossref
  • 49 Cystic Fibrosis Trust. Antibiotic Treatment for Cystic Fibrosis, 3rd edn. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group (Cystic Fibrosis Trust, Bromley, Kent, England, 2009) Available at: http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/AMntibiotic_treatment_for_Cystic_Fibrosis.pdf (accessed October 17, 2011).
  • 50 H Heijerman, E Westerman, S Conway, D Touw, G Döring, consensus working group. Inhaled medication and inhalation devices for lung disease in patients with CF: a European consensus. J Cyst Fibros. 2009;8:295-315 Crossref
  • 51 P Beringer. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001;7:434-440 Crossref
  • 52 KS McCoy. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2008;357:2310-2311
  • 53 BA Briesacher, AL Quittner, L Saiman, P Sacco, H Fouayzi, LM Quittell. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5 Crossref
  • 54 European Medicines Agency. Colobreathe. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001225/smops/Positive/human_smop_000270.jsp&mid=WC0b01ac058001d127&jsenabled=true (accessed October 29, 2011).
  • 55 DE Geller, J Weers, S Heuerding. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175-182 Crossref
  • 56 DE Geller, M Konstan, J Smith, S Noonberg, C Conrad. A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307-313 Crossref
  • 57 MW Konstan, DE Geller, P Minie, F Brockhaus, J Zhang, G Angyalosi. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol. 2011;46:230-238 Crossref
  • 58 MW Konstan, PA Flume, M Kappler, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10:54-61 Crossref
  • 59 PARI Pharma GmbH. eFlow® Technology Advanced Aerosol Delivery Platform. Available at: http://www.paripharma.com (accessed October 29, 2011).
  • 60 Arikace® (inhaled liposomal amikacin) (Insmed Incorporated, Monmouth Junction, NJ, 2011) Available at: http://www.insmed.com/arikace.php#p1 (accessed October 29, 2011).
  • 61 P Meers, M Neville, V Malinin, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61:859-868 Crossref
  • 62 L Dupont, P Minic, S Fustik, et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros. 2008;7(Suppl 2):S26 Abstract 102. Crossref
  • 63 P Minic, S Fustik, E Solyom, et al. A multi-cycle open-label study of nebulized liposomal amikacin (Arikace®) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros. 2011;10(Suppl 1):S55 Abstract 217. Crossref
  • 64 H Stass, S Baumann-Noss, H Delesen, et al. Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder. J Cyst Fibros. 2008;7(Suppl 2):S26 Abstract 103. Crossref
  • 65 P Bruinenberg, B Otulana, J Blanchard, et al. The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr Pulmonol. 2008;43(Suppl 31):344 Abstract 401.
  • 66 P King, O Lomovskaya, DC Griffith, JL Burns, MN Dudley. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother. 2010;54:143-148 Crossref
  • 67 P King, DM Citron, DC Griffith, O Lomovskaya, MN Dudley. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis. 2010;66:181-186 Crossref
  • 68 DE Geller, PA Flume, D Staab, R Fischer, JS Loutit, DJ Conrad, Mpex204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183:1510-1516 Crossref
  • 69 BC Trapnell, SA McColley, DG Kissner, et al. Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection. Am J Respir Crit Care Med. 2011; (in press).

Footnotes

a Ruhr University Paediatric Clinic at St Josef Hospital, Bochum, Germany

b Division of Human Development (Child Health), School of Clinical Sciences, Queen's Medical Centre, Nottingham, UK

c Nemours Children's Clinic, Orlando, FL, USA

* Corresponding author. Manfred Ballman, Alexandrinenstrasse 5, 44791 Bochum, Germany. Tel.: +49 234 509 2692